XML 124 R99.htm IDEA: XBRL DOCUMENT
v3.20.4

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) $ in Millions | 12 Months Ended |  |
--- | --- | --- | ---
Jan. 03, 2021 USD ($) | Dec. 29, 2019 USD ($) Segment | Dec. 30, 2018 USD ($) Segment | Oct. 31, 2020 USD ($) | Oct. 31, 2019 USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 82,584 | $ 82,059 | $ 81,581 |  |
Identifiable Assets | 174,894 | 157,728 |  |  |
Gain (Loss) on Disposition of Assets |  |  | 1,200 |  |
Contingent consideration reversal | (1,148) | $ 0 | $ 0 |  |
Number of segments | Segment |  | 3 | 3 |  |
Restructuring charges | 247 | $ 266 | $ 251 |  |
In-process research and development (Note 5) | $ 181 | $ 890 | 1,126 |  |
Percentage Change In Sales By Segment Of Business | 0.60% | 0.60% |  |  |
Pending Litigation |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Loss contingency, estimate of possible loss |  |  |  | $ 5,000 | $ 4,000
Medical Devices |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 22,959 | $ 25,963 | 26,994 |  |
Restructuring charges | 300 | 400 |  |  |
Regulation charge | 100 |  |  |  |
In-process research and development (Note 5) | 200 |  |  |  |
Litigation expense | $ 300 | $ 400 | 1,700 |  |
Restructuring Charge, Net of Accrual Adjustment |  |  | 600 |  |
Percentage Change In Sales By Segment Of Business | (11.60%) | (3.80%) |  |  |
Medical Devices | Interventional Solutions |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 3,046 | $ 2,997 | 2,646 |  |
Percentage Change In Sales By Segment Of Business | 1.60% | 13.30% |  |  |
Medical Devices | Diabetes Care |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers |  |  | 1,009 |  |
Consumer |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 14,053 | $ 13,898 | 13,853 |  |
Restructuring charges |  | 100 |  |  |
Litigation expense | $ 3,900 | $ 400 | 300 |  |
Percentage Change In Sales By Segment Of Business | 1.10% | 0.30% |  |  |
Consumer | Baby Care |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 1,517 | $ 1,675 | 1,858 |  |
Percentage Change In Sales By Segment Of Business | (9.40%) | (9.90%) |  |  |
Consumer | OTC |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 4,824 | $ 4,444 | 4,334 |  |
Percentage Change In Sales By Segment Of Business | 8.50% | 2.50% |  |  |
Consumer | Skin health/Beauty |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 4,450 | $ 4,593 | 4,382 |  |
Percentage Change In Sales By Segment Of Business | (3.10%) | 4.80% |  |  |
Consumer | Oral Care |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 1,641 | $ 1,528 | 1,555 |  |
Percentage Change In Sales By Segment Of Business | 7.40% | (1.70%) |  |  |
Pharmaceutical |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 45,572 | $ 42,198 | 40,734 |  |
Unrealized loss on securities |  |  | 200 |  |
Restructuring charges | 100 | 100 |  |  |
In-process research and development (Note 5) |  | 900 |  |  |
Litigation expense | $ 800 | 4,300 |  |  |
Research and Development Expense |  | $ 300 |  |  |
Percentage Change In Sales By Segment Of Business | 8.00% | 3.60% |  |  |
Pharmaceutical | Immunology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 15,055 | $ 13,950 | 13,120 |  |
Percentage Change In Sales By Segment Of Business | 7.90% | 6.30% |  |  |
Pharmaceutical | Oncology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 12,367 | $ 10,692 | 9,844 |  |
Percentage Change In Sales By Segment Of Business | 15.70% | 8.60% |  |  |
Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 3,148 | $ 2,623 | 2,573 |  |
Percentage Change In Sales By Segment Of Business | 20.00% | 1.90% |  |  |
Pharmaceutical | Stelara | Immunology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 7,707 | $ 6,361 | 5,156 |  |
Percentage Change In Sales By Segment Of Business | 21.10% | 23.40% |  |  |
Pharmaceutical | Tremfya | Immunology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 1,347 | $ 1,012 | 544 |  |
Percentage Change In Sales By Segment Of Business | 33.20% | 85.90% |  |  |
Pharmaceutical | Erleada | Oncology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 760 | $ 332 | 124 |  |
Pharmaceutical | IMBRUVICA | Oncology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 4,128 | $ 3,411 | 2,615 |  |
Percentage Change In Sales By Segment Of Business | 21.00% | 30.40% |  |  |
Pharmaceutical | DARZALEX | Oncology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 4,190 | $ 2,998 | 2,025 |  |
Percentage Change In Sales By Segment Of Business | 39.80% | 48.00% |  |  |
Pharmaceutical | OPSUMIT | Pulmonary Hypertension |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 1,639 | $ 1,327 | 1,215 |  |
Percentage Change In Sales By Segment Of Business | 23.50% | 9.20% |  |  |
Property, Plant and Equipment |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Long-Lived Assets | $ 18,766 | $ 17,658 |  |  |
Other Intangible Assets |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Long-Lived Assets | 89,795 | 81,282 |  |  |
Ci:z Holdings Co. Ltd. | Consumer |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Gain (Loss) on Sale of Equity Investments |  | 300 |  |  |
Alios Biopharma Inc and XO1 Limited | Pharmaceutical |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
In-process research and development (Note 5) |  |  | 1,100 |  |
XO1 |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Contingent consideration reversal |  |  | (200) |  |
Actelion | Pharmaceutical |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Acquisition related costs |  | 200 | 200 |  |
AMO | Medical Devices |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Acquisition related costs |  |  | 100 |  |
Auris Health |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Contingent consideration reversal | (1,148) |  |  |  |
Auris Health | Medical Devices | Other Income [Member] |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Contingent consideration reversal | (1,100) |  |  |  |
Auris Health | Pharmaceutical |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Acquisition related costs |  | 100 |  |  |
United States |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 43,133 | $ 42,097 | 41,884 |  |
Percentage Change In Sales By Segment Of Business | 2.50% | 0.50% |  |  |
United States | Medical Devices |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 11,036 | $ 12,384 | 12,837 |  |
Percentage Change In Sales By Segment Of Business | (10.90%) | (3.50%) |  |  |
United States | Medical Devices | Interventional Solutions |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 1,452 | $ 1,443 | 1,283 |  |
Percentage Change In Sales By Segment Of Business | 0.60% | 12.50% |  |  |
United States | Medical Devices | Diabetes Care |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers |  |  | 371 |  |
United States | Consumer |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 6,362 | $ 5,839 | 5,761 |  |
Percentage Change In Sales By Segment Of Business | 9.00% | 1.40% |  |  |
United States | Consumer | Baby Care |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 376 | $ 362 | 422 |  |
Percentage Change In Sales By Segment Of Business | 3.70% | (14.20%) |  |  |
United States | Consumer | OTC |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 2,460 | $ 2,010 | 1,850 |  |
Percentage Change In Sales By Segment Of Business | 22.40% | 8.60% |  |  |
United States | Consumer | Skin health/Beauty |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 2,350 | $ 2,392 | 2,403 |  |
Percentage Change In Sales By Segment Of Business | (1.70%) | (0.40%) |  |  |
United States | Consumer | Oral Care |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 683 | $ 621 | 637 |  |
Percentage Change In Sales By Segment Of Business | 9.90% | (2.50%) |  |  |
United States | Pharmaceutical |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 25,735 | $ 23,874 | 23,286 |  |
Percentage Change In Sales By Segment Of Business | 7.80% | 2.50% |  |  |
United States | Pharmaceutical | Immunology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 10,175 | $ 9,641 | 9,073 |  |
Percentage Change In Sales By Segment Of Business | 5.50% | 6.30% |  |  |
United States | Pharmaceutical | Oncology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 5,092 | $ 4,299 | 4,331 |  |
Percentage Change In Sales By Segment Of Business | 18.50% | (0.70%) |  |  |
United States | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 2,133 | $ 1,684 | 1,651 |  |
Percentage Change In Sales By Segment Of Business | 26.60% | 2.00% |  |  |
United States | Pharmaceutical | OPSUMIT |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Percentage Change In Sales By Segment Of Business |  | 9.40% |  |  |
United States | Pharmaceutical | Stelara | Immunology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 5,240 | $ 4,346 | 3,469 |  |
Percentage Change In Sales By Segment Of Business | 20.60% | 25.30% |  |  |
United States | Pharmaceutical | Tremfya | Immunology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 926 | $ 764 | 453 |  |
Percentage Change In Sales By Segment Of Business | 21.30% | 68.50% |  |  |
United States | Pharmaceutical | Erleada | Oncology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 583 | $ 297 | 124 |  |
Percentage Change In Sales By Segment Of Business | 96.10% |  |  |  |
United States | Pharmaceutical | IMBRUVICA | Oncology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 1,821 | $ 1,555 | 1,129 |  |
Percentage Change In Sales By Segment Of Business | 17.10% | 37.70% |  |  |
United States | Pharmaceutical | DARZALEX | Oncology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 2,232 | $ 1,567 | 1,203 |  |
Percentage Change In Sales By Segment Of Business | 42.40% | 30.30% |  |  |
United States | Pharmaceutical | OPSUMIT | Pulmonary Hypertension |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 1,008 | $ 766 | 700 |  |
Percentage Change In Sales By Segment Of Business | 31.70% |  |  |  |
Non-US |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 39,451 | $ 39,962 | 39,697 |  |
Percentage Change In Sales By Segment Of Business | (1.30%) | 0.70% |  |  |
Non-US | Medical Devices |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 11,923 | $ 13,579 | 14,157 |  |
Percentage Change In Sales By Segment Of Business | (12.20%) | (4.10%) |  |  |
Non-US | Medical Devices | Interventional Solutions |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 1,594 | $ 1,554 | 1,363 |  |
Percentage Change In Sales By Segment Of Business | 2.60% | 14.00% |  |  |
Non-US | Medical Devices | Diabetes Care |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers |  |  | 638 |  |
Non-US | Consumer |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 7,691 | $ 8,059 | 8,092 |  |
Percentage Change In Sales By Segment Of Business | (4.60%) | (0.40%) |  |  |
Non-US | Consumer | Baby Care |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 1,141 | $ 1,313 | 1,436 |  |
Percentage Change In Sales By Segment Of Business | (13.10%) | (8.60%) |  |  |
Non-US | Consumer | OTC |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 2,364 | $ 2,434 | 2,484 |  |
Percentage Change In Sales By Segment Of Business | (2.90%) | (2.00%) |  |  |
Non-US | Consumer | Skin health/Beauty |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 2,100 | $ 2,201 | 1,979 |  |
Percentage Change In Sales By Segment Of Business | (4.60%) | 11.20% |  |  |
Non-US | Consumer | Oral Care |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 958 | $ 906 | 918 |  |
Percentage Change In Sales By Segment Of Business | 5.70% | (1.20%) |  |  |
Non-US | Pharmaceutical |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 19,837 | $ 18,324 | 17,448 |  |
Percentage Change In Sales By Segment Of Business | 8.30% | 5.00% |  |  |
Non-US | Pharmaceutical | Immunology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 4,880 | $ 4,309 | 4,047 |  |
Percentage Change In Sales By Segment Of Business | 13.20% | 6.50% |  |  |
Non-US | Pharmaceutical | Oncology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 7,275 | $ 6,393 | 5,513 |  |
Percentage Change In Sales By Segment Of Business | 13.80% | 16.00% |  |  |
Non-US | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 1,015 | $ 939 | 922 |  |
Percentage Change In Sales By Segment Of Business | 8.20% | 1.90% |  |  |
Non-US | Pharmaceutical | OPSUMIT |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Percentage Change In Sales By Segment Of Business |  | 9.00% |  |  |
Non-US | Pharmaceutical | Stelara | Immunology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 2,467 | $ 2,015 | 1,687 |  |
Percentage Change In Sales By Segment Of Business | 22.40% | 19.40% |  |  |
Non-US | Pharmaceutical | Tremfya | Immunology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 421 | $ 248 | 91 |  |
Percentage Change In Sales By Segment Of Business | 69.90% |  |  |  |
Non-US | Pharmaceutical | Erleada | Oncology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 176 | 35 | 0 |  |
Non-US | Pharmaceutical | IMBRUVICA | Oncology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 2,307 | $ 1,856 | 1,486 |  |
Percentage Change In Sales By Segment Of Business | 24.30% | 24.90% |  |  |
Non-US | Pharmaceutical | DARZALEX | Oncology |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 1,958 | $ 1,430 | 822 |  |
Percentage Change In Sales By Segment Of Business | 36.90% | 73.90% |  |  |
Non-US | Pharmaceutical | OPSUMIT | Pulmonary Hypertension |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | $ 631 | $ 562 | 515 |  |
Percentage Change In Sales By Segment Of Business | 12.30% |  |  |  |
Corporate, Non-Segment |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Other Non Long Lived Assets | $ 66,333 | 58,788 |  |  |
Corporate, Non-Segment | General Corporate |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Long-Lived Assets | 1,029 | 1,049 |  |  |
Identifiable Assets | 31,803 | 25,356 |  |  |
Operating Segments |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | 82,584 | 82,059 | 81,581 |  |
Long-Lived Assets | 107,532 | 97,891 |  |  |
Operating Segments | Medical Devices |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Identifiable Assets | 49,578 | 49,462 |  |  |
Operating Segments | Consumer |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Identifiable Assets | 27,355 | 26,618 |  |  |
Operating Segments | Pharmaceutical |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Identifiable Assets | 66,158 | 56,292 |  |  |
Unrealized Gain (Loss) on Securities | 500 | 600 |  |  |
Operating Segments | NIZORAL | Consumer |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Gain (Loss) on Disposition of Assets |  |  | 300 |  |
Operating Segments | PANCREASE | Pharmaceutical |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Gain (Loss) on Disposition of Assets |  |  | 200 |  |
Operating Segments | LifeScan | Medical Devices |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Gain (Loss) on Disposition of Business |  |  | 500 |  |
Operating Segments | United States |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | 43,133 | 42,097 | 41,884 |  |
Long-Lived Assets | 49,951 | 41,528 |  |  |
Operating Segments | Europe |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | 18,980 | 18,466 | 18,753 |  |
Long-Lived Assets | 49,363 | 48,015 |  |  |
Operating Segments | Western Hemisphere excluding U.S. |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | 5,335 | 5,941 | 6,113 |  |
Long-Lived Assets | 2,734 | 2,862 |  |  |
Operating Segments | Asia-Pacific, Africa |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Sales to Customers | 15,136 | 15,555 | $ 14,831 |  |
Long-Lived Assets | $ 5,484 | $ 5,486 |  |  |
Wholesaler 1 | Sales Revenue, Net |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Concentration risk (as a percent) | 16.00% | 15.00% | 14.00% |  |
Wholesaler 2 | Sales Revenue, Net |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Concentration risk (as a percent) | 12.00% | 12.00% | 11.00% |  |
Wholesaler 3 | Sales Revenue, Net |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Concentration risk (as a percent) | 12.00% | 11.00% |  |  |
AdvancedSterilizationProducts |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Gain (Loss) on Disposition of Business |  | $ 2,000 |  |  |
AdvancedSterilizationProducts | Operating Segments | Medical Devices |  |  |  |  |
Revenues from External Customers and Long-Lived Assets [Line Items] |  |  |  |  |
Gain (Loss) on Disposition of Business |  | $ 2,000 |  |  |

X
- Definition Other non long lived assets. + References No definition available. + Details
Name: | jnj_OtherNonLongLivedAssets
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Regulation charge + References No definition available. + Details
Name: | jnj_RegulationCharge
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Restructuring Charge, Net of Accrual Adjustment + References No definition available. + Details
Name: | jnj_RestructuringChargeNetofAccrualAdjustment
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 + Details
Name: | us-gaap_Assets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_GainLossOnDispositionOfAssets1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684 + Details
Name: | us-gaap_GainLossOnSaleOfBusiness
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence. + References No definition available. + Details
Name: | us-gaap_GainLossOnSaleOfEquityInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reflects the estimated amount of loss from the specified contingency as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248 + Details
Name: | us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599 + Details
Name: | us-gaap_NoncurrentAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References No definition available. + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_RestructuringCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of unrealized gain (loss) recognized in the income statement on unsold other securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_UnrealizedGainLossOnSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease), resulting in a loss, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period. + References No definition available. + Details
Name: | us-gaap_UnrealizedLossOnSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_DiabetesCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ErleadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_CizHoldingsCo.Ltd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_AliosBiopharmaIncandXO1LimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_XO1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_ActelionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_AMOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_NIZORALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_PANCREASEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=jnj_LifeScanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=jnj_Wholesaler1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=jnj_Wholesaler2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=jnj_Wholesaler3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_AdvancedSterilizationProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |